CALGARY, ALBERTA / ACCESSWIRE / March 18, 2015 / Further to its news releases of January 15, 2015, and March 13, 2015, Avagenesis Corp. (TSX VENTURE:VVA) ("Avagenesis" or the "Company") today announced the closing of the transactions contemplated in the share exchange agreement dated as of January 15, 2015 between Avagenesis and Curastem Biomedical Corp., including the closing of a private placement by Curastem for gross proceeds of $696,992.

The acquisition is subject to final approval by the TSX Venture Exchange.

About Avagenesis Corp.

Avagenesis is a biotechnology company engaged in the commercialization of medical technologies for use in the practice of regenerative medical aesthetics. Avagenesis' development activities are focused on the complex task of efficiently isolating high quality, viable and potent adipose-derived adult stem cells and regenerative cells using patent-pending and patented bioprocessing and cell isolation technology.

Neither the Exchange nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.

Further Information

For further information, please contact:

Avagenesis Corp.
Alan Tam, PFP, CPA, CA
Chief Financial Officer
Telephone:(604)377-7575

SOURCE: Avagenesis Corp.